BioCardia Seeks FDA Accelerated Approval for CardiAMP System to Treat Ischemic Heart Failure
BioCardia seeks FDA accelerated approval for its CardiAMP device, promising faster access for ischemic heart failure patients.
3 minutes to read
BioCardia Inc
BioCardia Inc. (BIOC) – Cardiovascular Biotech Snapshot & Market Outlook
BioCardia Inc. (BIOC) is a U.S. biotech focused on cardiovascular therapies, with a $12 M market cap and current negative P/E. No new news yet—watch regulatory filings and earnings for growth clues.
2 minutes to read
BioCardia Inc: Navigating Financial Challenges Amidst Promising Cardiovascular Innovations
BioCardia Inc, a biotech company focused on cardiovascular disease solutions, faces significant financial and competitive challenges that threaten its future prospects despite its promising mission.
2 minutes to read